-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E6ZozhbOAHJV+D3NXDlB1TURiqa3MyLtUyTpjUzzc5JCDqJp1hE6VMccOTuiuiDn
 ppJ5hk2UhoZjrgSm/CvNnQ==

<SEC-DOCUMENT>0001019687-02-001134.txt : 20020607
<SEC-HEADER>0001019687-02-001134.hdr.sgml : 20020607
<ACCEPTANCE-DATETIME>20020606160605
ACCESSION NUMBER:		0001019687-02-001134
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20020530
ITEM INFORMATION:		Acquisition or disposition of assets
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20020606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08765
		FILM NUMBER:		02672284

	BUSINESS ADDRESS:	
		STREET 1:		1533 MONROVIA AVENUE
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92663
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		1533 MONROVIA AVENUE
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92663

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>biomerica_8k-060502.txt
<TEXT>
<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                                WASHINGTON, D.C.

                                    FORM 8-K

                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                  May 30, 2002
                Date of Report (date of earliest event reported)


                                 BIOMERICA, INC.
             (Exact Name of Registrant as Specified in its Charter)

   Delaware                           0-8765                    95-2645573
   --------                           ------                    ----------
(State or Other                    (Commission                (IRS Employee
Jurisdiction of                    File Number)               Identification
                                                                  Number)

                              1533 Monrovia Avenue
                         Newport Beach, California 92663
                         -------------------------------
                     (Address of Principal Executive Offices
                               Including Zip Code)

                                  949-645-2111
                                  ------------
                         (Registrant's Telephone Number,
                              Including Area Code)


                                   ----------
                    (Former Name or Former Address if Changed
                               Since Last Report)


                                   Page 1 of 4



<PAGE>

Item 2.  Acquisition or Disposition of Assets.

         On May 30, 2002, Biomerica sold its controlling interest of 13,350,000
shares of Allergy Immuno Technologies, Inc. (ALIM.OB) common stock plus a
promissory note evidencing an obligation from Allergy Immuno Technologies to
Biomerica in the amount of $225,282, in a private sale to LDM Holdings, Inc. The
proceeds of the sale were $212,500. Biomerica still retains 255,575 shares of
Allergy Immuno Technologies, Inc. common stock. Prior to the sale, Biomerica
owned approximately 75.7% of the outstanding shares of Allergy Immuno
Technologies and consolidated the Allergy Immuno Technologies financials with
those of Biomerica.


(C)      Exhibits

         99.1 Press Release dated June 4, 2002.



<PAGE>






         SIGNATURES
         ----------


         Pursuant to the requirements of the Secutities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated:  June 5, 2002                            Biomerica, Inc.



                                                By: /S/ Zackary S. Irani
                                                    --------------------------
                                                    Zackary S. Irani
                                                    Chairman





</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>biomerica_ex99-1.txt
<TEXT>
<PAGE>
EXHIBIT 99.1


                                                                            NEWS
                                                           FOR IMMEDIATE RELEASE
- --------------------------------------------------------------------------------
                                                        Contact: Zack Irani, CEO
                                                                    949-645-2111



       BIOMERICA SELLS CONTROLLING INTEREST IN ALLERGY IMMUNO TECHNOLOGIES

         NEWPORT BEACH, CA., June 4, 2002 - Biomerica, Inc. (NASDAQ: BMRAC), a
global medical technology company, today announced the cash sale of its
controlling interest of 13,350,000 shares of Allergy Immuno Technologies, Inc.
(AIT) (OTC BB: ALIM) to LDM Holdings, Inc., Orlando, Florida. Proceeds of the
sale exceeded $212,000.

         AIT operated a clinical laboratory and was involved in developing
methods for the treatment of allergies. After several years of un-profitability,
the operations of AIT were discontinued in March 2002. Prior to the stock sale,
Biomerica owned approximately 75.7 percent of the outstanding shares of AIT and
its financial results were consolidated with those of Biomerica.

ABOUT BIOMERICA (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company,
based in Newport Beach, CA. The Company's diagnostic division manufactures and
markets advanced diagnostic products used in the home, in hospitals, and in
physician's offices for the early detection of medical conditions and diseases.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for forward-looking statements. Certain information included in this press
release (as well as information included in oral statements or other written
statements made or to be made by Biomerica) contains statements that are
forward-looking; such as statements relating to intended launch dates, market
size, expansion, expected orders, leading market positions, anticipated future
revenues or production volume of the company, success of product and new product
offerings. Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results in the future,
and accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential
risks and uncertainties include, among others, fluctuations in the Company's
operating results due to its business model and expansion plans, downturns in
international and or national economies, the Company's ability to raise
additional capital, the competitive environment in which the Company will be
competing, and the Company's dependence on strategic relationships. The Company
is under no obligation to update any forward-looking statements after the date
of this release.






</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
